Diuretics in HF

- Diuretics are commonly used despite the lack of evidence for survival benefit.
- Diuretics can relieve symptoms in patient with HF which are the result of excessive fluid retention.

IV Infusions Bumetanide

Furosemide

Torsemide

• Diuretics are classified based on their site of action.

Loop Diuretics

• Block the Na-K-2Cl cotransporter at the luminal side of the thick ascending limb of the loop of Henle.

• Result in \uparrow Na excretion, \uparrow K excretion, \uparrow Cl excretion.

Pharmacokinetic

- Varied absorption, albumin bound.
- All loop diuretics have the same efficacy (when administered in comparable doses,

they exert comparable effects).

• Onset = 30 - 60 mins.


Drug	Initial Dose	Maximum Single Dose
Loop Diuretics		
Bumetanide	1.0 mg	4 to 8 mg
Furosemide	40 mg	160 to 200 mg
Torsemide	10 mg	100 to 200 mg

Table 5. Intravenous Diuretic Medications Useful for the

Treatment of Severe Heart Failure

1-mg IV load then 0.5 to 2 mg per hour infusion 40-mg IV load then 10 to 40 mg per hour infusion 20-mg IV load then 5 to 20 mg per hour infusion

ACC/AHA HF guideline 2009



Pharmacodynamics: (Brater. Semin Nephrol 2011;31:483-494)

- Loop diuretic has a sigmoid dose-response curve.
- Not response until reaching a threshold dose.

• Once the plateau is reached, the higher doses do not cause a much greater response.

• Once the plateau is reached, if more fluid loss is needed, the drug should be given more frequently.

Clinical pearl

- Varied in absorption of furosemide = unreliable dosing.
- Adverse effect: Ototoxic, hypoK, hyperUric (gout), hyperglycemia, hypoMg.

• Diuretics decrease intravascular volume. Patient may develop relative hypovolemic if capillary refill rate is abnormal

Dose Tx mg T2x mg T3x mg T4x mg T5x mg

DOSE trial: (NEJM 2011;364:797) • Double blind RCT of furosemide in pts with HF (N=308)

- 2x2 factorial:
- High-dose (2.5xhome dose) vs. low-dose (1x home dose)
- IV bolus vs. IV continuous infusion At 72 hours:
- 1° endpoints: no statistic
 significant difference in patients'
 global assessment of symptoms or in
 Δ renal function in any group.
 2° endpoints: High-dose was

associated with greater wt loss, net volume loss, ↑numer of pt c WRF(>0.3), ↓dyspnea.

Diuretic Resistant (ter Maaten. Nat.Rev.Cardiol 2015;12:184-192)

- First, rule out poor compliance to medications, salt or fluid restriction.
- If suboptimal dose or bioavailability:
- Increase doses, if not reaching response dose.
- Increase frequency, if already at response dose.
- Switch to a drug that has better bioavailability (torsemmide or bumetnide), if given orally.
 Switch to IV form, switch to IV continuous infusion.
- Adding second diuretics eg. thiazide, spironolactone, tolvaptan.
- Ultrafiltration: Greater control of fluid removal rate but no greater weight loss when compared to diuretics and more adverse effect (CARRESS-HF NEJM2012).

Adding Second Diuretics

Thiazide

• Block the Na-Cl symporter at the distal tubule.

• Synergy effect in patient with chronic use of loop diuretic because loop cause ↑[Na] reabsorption in distal tubule and secondary tubule hypertrophy.

- Suggested dose: HCTZ 50-100 mg oral daily.
- Traditionally given 30 mins before furosemide.
- S/E: HypoK, hypoNa.

Spironolactone

An aldosterone blocker

- Work at the collecting duct.
- A low dose as guideline recommendation for chronic HFrEF management to improve survival.

does not have diuretic effect. Need 50-75 mg/day to reach natriuretic effect.

• S/E: 2% serious hyperK, 10% gynecomastia.

Tolvaptan (EVEREST JAMA2007)

- A vasopressin antagonist
- Block the V2 receptor in the collecting tubule \rightarrow 1 water excretion "aquaresis"
- Starting dose: 7.5 15 mg oral daily.

• In patients with ADHF, adding tolvaptan improved weight loss and congestion (dyspnea, orthopnea, JVD, edema, rales) in first few days to wk but no effect on long-term mortality or rehospitalization.

• S/E: 6% dry mouth, 14% thirst, 1.5% hyperNa (mean \uparrow of 4 mEq/L). Minimal effect on hemodynamics, K, and Cr. Contraindicate in \uparrow AST/ALT

• Patient must not on fluid restriction when using tolvaptan.

Clinical pearl

• Alternative strategies (limited evidence) include acetazolamide, mannitol and hypertonic saline.

• Neither low dose dopamine nor nesiritide can improve urine output or renal function in patient with AHF and diuretic resistant (ROSE JAMA2013).

